Feature Film Focuses on Biological Dentistry and Bone Regeneration
Regenerating Bone. Rebuilding Lives. Restoring Dreams.
Wednesday, January 28, 2026 | Norwood, NJ
Osteogene Tech Corp (Osteogene), a commercial-stage bone regenerative company, today announced that Daniel S. Oh, Ph.D., Chief Science Officer of Osteogene, was selected to participate in the upcoming feature documentary “Bye Ol’ Dentistry,” produced by Lolli Brands Entertainment. The documentary focuses on the groundbreaking progress in dentistry and bone regeneration, premiering globally on Prime Video and Biohack Yourself Magazine, which was released on January 21, 2026.
“It is an honor to be selected for this important documentary among various dental experts across the globe in bone regeneration,” said Dr. Oh, co-founder of Osteogene. “We look forward to pushing the boundaries of bone regeneration as we enter a new growth phase of the company. We hope our strategic collaborations with hospitals and institutions will continue to help advance our approved solutions for more patients across the country.”
The film follows one family’s full biological dental transformation, revealing how oral health fuels whole-body healing. Behind their journey are the tools, practitioners, and innovations leading the new era of dentistry. In addition, the documentary will feature the following:
- Exclusive interviews with the pioneers of biological dentistry
- Real-world results backed by data-driven protocols
- Products and techniques trusted by top professionals
- Supplement systems redefining patient care
Dr. Oh’s life work is embodied in Osteogene’s flagship product, InRoad®, the first FDA-cleared engineered bioceramic bone graft designed to promote natural bone regeneration. InRoad® enhances blood absorption and circulation, emulates the biological microenvironment of bone without donor risks, and simplifies clinical procedures. This innovation has applications not only in dentistry but also in maxillofacial and orthopedic surgery.
With more than 25 years of experience across academia and industry, Dr. Oh has dedicated his career to advancing biomaterials and biomedical engineering. Widely recognized as an innovator in translational medical research, he bridges material science, biology, and clinical applications at the macro-, micro-, and nano-scales.
Following FDA clearance and the necessary patient data collection period, InRoad® experienced a surge in adoption among the healthcare community in 2025, with sales growing more than 500% compared to 2024.
Why it is called “InRoad” and how it works:
It is called InRoad because each granule contains internal, road-like channels. These micro-channels induce capillary action, allowing blood to rapidly soak into the graft when InRoad is placed into a defect.
Adequate blood flow and circulation are essential for successful bone regeneration. Because these micro-sized tubules inherently promote capillary action, the 50–70 µm channels engineered within each septum of InRoad® enable sustained blood flow and circulation throughout the graft.
Why “InRoad” works?
Heterogeneous cells migrate with blood flow into the grafted area and attach to both the outer and inner surfaces of the micro-channels. This rapid cell population expansion and extracellular matrix production create a biological environment that promotes bone regeneration. This optimized spatiotemporal configuration enhances robust osteoconduction and leads to consistent, solid bone regeneration at the defect site.
About Osteogene
Osteogene Tech Corp is dedicated to bettering the health and quality of life for people around the world as a regenerative medicine with its research and development efforts in the bone graft industry. The company has created an innovative bone graft technology called InRoad®, a cutting-edge osteoconductive, bioceramic bone graft specifically designed for dental applications. The company is breaking pre-existing barriers in the industry to enable medical professionals to better help their patients improve bone regeneration and restoration after dental, maxillofacial and orthopedic surgical procedures.
The company’s leading scientists and researchers continue to work diligently every day to expand the application of this revolutionary product to reach as many people around the world as possible. For more information about InRoad®, please visit the Osteogene website at www.osteogene.com.
###
Media Contact:
Dawn Fallon
New Dawn Communications LLC
E: dfallon@newdawncomms.com
P: 732-771-7808
Source: Osteogene